罗氏证实吉地司群+依维莫司Met联合主要终点在ER阳性HER 2阴性乳腺癌患者中产生统计学显着的结果

2025-09-22 14:27

evERA met its co-primary endpoints; giredestrant plus everolimus demonstrated significant benefit in ITT and ESR1-mutated populations in the post-CDK inhibitor setting, compared with standard of care plus everolimus
The all-oral combination was well tolerated and adverse events were consistent with the known safety profiles of the individual study treatments; no new safety signals were observed
evERA is the first positive head-to-head Phase III trial investigating an all-oral selective estrogen receptor degrader-containing regimen versus a standard of care combination
Data will be presented at an upcoming medical meeting and shared with health authorities